NEW YORK, Aug. 2 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals proudly announces that its common shares are now also listed on the Frankfurt Stock Exchange under the ticker symbol OJU.
The CEO Nadav Kidron stated, “We hope to achieve another milestone with the listing on the Frankfurt Stock Exchange to help us with our long term focus...this listing should help us gain visibility and support in the European market.”
Trading both on the OTCBB and on the Frankfurt Stock Exchange may help Oramed build a better investor foundation to move forward. The Frankfurt Stock Exchange provides full-service trading capabilities, which include a trading floor as well as an electronic trading exchange, XETRA.
About the Frankfurt Stock Exchange
The Frankfurt Stock Exchange, known as the Frankfurter Wertpapierborse (FWB) is one of the world’s largest trading centers for securities. Operated by the Deutsche Borse AG, FWB is the largest of the eight Germany stock exchanges. The Deutsche Borse’s products and services portfolio cover the entire process chain including securities and derivatives trading, transaction settlement, the provision of market information, as well as the development and operation of electronic trading systems. For more information, visit the Deutsche Borse at: http://deutsche-boerse.com.
About Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals’ is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information please visit our website at http://www.oramedpharma.com.
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comhttp://www.oramedpharma.com Safe Harbor Statement
This news release contains statements, which may constitute “forward-looking statements.” Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc. as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that the listing on the Frankfurt Stock Exchange may help Oramed gain visibility and support in the European market and may help us build a better investor foundation; and that we are pursuing the development of oral delivery solutions for other drugs and vaccines. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that competitors may invent better technology; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company’s latest 10-QSB filed with the SEC on July 17, 2006.
Oramed Pharmaceuticals, Inc.
CONTACT: Vinisha Agnihotri, of Oramed Pharmaceuticals, Inc.,+1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com/
